| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6503745 | BIOCRYST | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
Nov, 2019
(4 years ago) | |
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(2 years from now) | |
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(3 years from now) | |
Rapivab is owned by Biocryst.
Rapivab contains Peramivir.
Rapivab has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Rapivab are:
- US6503745
- US6562861
Rapivab was authorised for market use on 19 December, 2014.
Rapivab is available in solution;intravenous dosage forms.
Rapivab can be used as treatment of acute uncomplicated influenza in patients 6 months and older.
Drug patent challenges can be filed against Rapivab from 19 December, 2018.
The generics of Rapivab are possible to be released after 07 May, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 20, 2020 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using PERAMIVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of acute uncomplicated influenza in patients 6 months and older
Dosage: SOLUTION;INTRAVENOUS
RAPIVAB family patents
